Trevena Reports Fourth Quarter 2023 Results and Provides Corporate Update
April 01, 2024 07:00 ET
|
Trevena, Inc.
TRV045, novel S1P receptor modulator for chronic pain and epilepsy, advances toward important milestones in both non-clinical and clinical studies Company announces reduction of OLINVYK commercial...
Trevena Announces the Closing of $4 Million Concurrent Private Placement and Warrant Exercise
December 28, 2023 14:00 ET
|
Trevena, Inc.
CHESTERBROOK, Pa., Dec. 28, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (“Trevena” or the “Company”) (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel...
Trevena Inc. Announces $4 Million Concurrent Private Placement and Warrant Exercise
December 27, 2023 09:10 ET
|
Trevena, Inc.
CHESTERBROOK, Pa., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Trevena Inc. (“Trevena” or the “Company”) (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel...
Trevena Announces TRV045 Presentation at the American College of Neuropsychopharmacology 62nd Annual Meeting
December 04, 2023 07:02 ET
|
Trevena, Inc.
-- Presentation highlighted promising results of TRV045 in nonclinical models of neuropathic pain including mechanical and cold-stimulus evoked nociceptive pain in a dose-related manner TRV045...
Trevena Awarded OLINVYK Agreement with Premier, Inc.
December 04, 2023 07:00 ET
|
Trevena, Inc.
CHESTERBROOK, Pa., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Trevena Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
Trevena Announces Acceptance of Abstract Examining the Use of OLINVYK in Patients with Acute Burn Injuries
November 30, 2023 07:00 ET
|
Trevena, Inc.
CHESTERBROOK, Pa., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
Trevena Reports Third Quarter 2023 Results and Provides Business Update
November 14, 2023 07:00 ET
|
Trevena, Inc.
Company previously announced statistically significant topline TRV045 data from two proof-of-concept studies evaluating S1PR mechanism of action and CNS target engagement Company reported favorable...
Trevena to Release Third Quarter 2023 Financial Results on November 14, 2023
November 09, 2023 07:00 ET
|
Trevena, Inc.
CHESTERBROOK, Pa., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
Trevena Reports Favorable TRV045 Topline Safety and Tolerability Data from Proof-of-Concept Studies
October 16, 2023 07:00 ET
|
Trevena, Inc.
TRV045 was well tolerated with results generally consistent with prior first-in-human study No drug-related adverse events and no serious adverse events reported No drug-related lymphopenia,...
Trevena Announces Completion of Initial Analysis of OLINVYK Continuous Respiratory Monitoring Data from VOLITION Study and Presentation at American Society of Anesthesiologists Conference
October 02, 2023 07:00 ET
|
Trevena, Inc.
Continuous respiratory monitoring data for ~200 complex surgical patients treated with IV OLINVYK at Cleveland Clinic and Wake Forest Baptist Health in the VOLITION study provides insights into...